Health-related quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is not different than cytoreductive surgery alone in primary ovarian cancer patients

Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery (CRS) raises concerns about poor health-related quality of life (HRQOL) outcomes in ovarian cancer (OC) patients. CRS/HIPEC has not been shown to decrease long-term HRQOL in other malignancies; however, the evidence in OC is inconsistent. We analyzed the HRQOL outcomes of primary OC patients with peritoneal metastasis (PM) enrolled in phase II randomized study (NCT#: 02124421).